It’s possible that HIV could be prevented by an annual shot — at least, that’s what new data from Gilead suggests. The drug company has been developing a new HIV drug called lenacapavir, which until now has been tested just twice a year. Scientists have been tweaking the drug’s formulation and recently found in a 40-person...
Tag: <span>HIV</span>
Post
Two-Drug HIV Regimen Matches Three-Drug Options in Long-Term Treatment Success
Edited by Shreyasi Asthana January 14, 2025 022 Add to Email Alerts TOPLINE: Among treatment-naive people with HIV (PWH), dolutegravir/lamivudine demonstrates effectiveness comparable with those of the commonly prescribed three-drug regimens but offers better persistence and lower discontinuation rates at 96 weeks. METHODOLOGY: TAKEAWAY: IN PRACTICE: “These findings are consistent with the results of clinical...
Post
Transforming HIV diagnosis: A low-cost, point-of-care detection solution
by Aerospace Information Research Institute, Chinese Academy of Sciences Detection specificity of the platform. Credit: Microsystems & Nanoengineering (2024). DOI: 10.1038/s41378-024-00822-1 A team of researchers from the University of Florida has developed an innovative handheld device for human immunodeficiency virus (HIV) detection that combines paper-based sample preparation with real-time isothermal amplification. This low-cost, portable platform promises rapid...
Post
HIV protein switch may help virus squeeze into host cell nucleus
by Pittsburgh Supercomputing Center Credit: Pixabay/CC0 Public Domain Supercomputer simulations have revealed how changes in the shape of the HIV-1 capsid protein may help the virus squeeze its inner core into the host cell’s nuclear membrane. The findings, by a University of Pittsburgh team using the Bridges-2 system at the Pittsburgh Supercomputing Center, suggest how the...
Post
Scientists develop new natural killer cell strategy to target HIV
by The Wistar Institute Credit: Pixabay/CC0 Public Domain Researchers at The Wistar Institute’s HIV Cure and Viral Diseases Center have successfully identified a new approach using natural killer (NK) cells to target and kill the HIV-positive cells that allow the virus to persist. Wistar scientists have labeled this new approach “NuKES”: Natural Killer Enhancement Strategy. Led...
Post
Cancer-fighting compound shows immense potential to eradicate HIV
by Adam Hadhazy, Stanford University Design of EBC-46 analogs. Credit: Science Advances (2025). DOI: 10.1126/sciadv.ads1911 A compound with the unpresuming designation of EBC-46 has made a splash in recent years for its cancer-fighting prowess. Now a new study led by Stanford researchers has revealed that EBC-46 also shows immense potential for eradicating human immunodeficiency virus (HIV) infections. Compared...
Post
Most Older Adults With HIV Miss Bone Density Scans
Heidi Splete Nearly 90% of people older than 50 years living with HIV have not undergone bone mineral density testing, based on data from approximately 12,000 individuals. Factors including chronic inflammation, immune dysfunction, and side effects from antiretroviral therapy may contribute to accelerated aging in people with HIV, wrote Veronica J. Brady, PhD, of the...
Post
New rule allows HIV-positive organ transplants
by Carla K. Johnson Surgical instruments and supplies lay on a table during a kidney transplant surgery at MedStar Georgetown University Hospital in Washington D.C., Tuesday, June 28, 2016. Credit: AP Photo/Molly Riley, File People with HIV who need a kidney or liver transplant will be able to receive an organ from a donor with...
Post
Promising tuberculosis therapy safe for patients with HIV, finds study
October 1, 2024 by Texas Biomedical Research Institute Researchers compare the impacts of cART by itself versus cART plus the IDO inhibitor in lung tissue of nonhuman primates with both TB and SIV. Left: Following just cART, significantly more IDO is detected in pink. Right: With the IDO inhibitor and cART, immune cells recruited to...
Post
Trial finds metabolic risk contributes to diabetes onset in people with HIV
For people with HIV (PWH) with low-to-moderate atherosclerotic cardiovascular disease (ASCVD) risk, metabolic risk factors contribute to new-onset diabetes mellitus (DM) among those treated with pitavastatin or placebo, according to a study published online Oct. 8 in the Annals of Internal Medicine. Kathleen V. Fitch, from Massachusetts General Hospital and Harvard Medical School in Boston, and colleagues examined...